Fibrinolytic system

FDA Approves First Treatment for Patients with Plasminogen Deficiency, a Rare Genetic Disorder

Retrieved on: 
Friday, June 4, 2021
Blood, Anatomy, Fibrinolytic system, Body fluids, Hematology, Plasmin, Orphan drug, Thrombus, Plasminogen activator, Fibrinolysis

"Today's approval helps address an unmet medical need for individuals affected by this rare genetic disease."

Key Points: 
  • "Today's approval helps address an unmet medical need for individuals affected by this rare genetic disease."
  • Individuals with this disease lack a protein called plasminogen, which is responsible for the ability of the body to break down fibrin clots.
  • Treatment with Ryplazim helps to increase the plasma level of plasminogen - enabling a temporary correction of the plasminogen deficiency and reduction or resolution of the lesions.
  • The FDA granted Ryplazim Orphan Drug designation, which provides incentives to assist and encourage drug development for rare diseases.

Global D-dimer Testing Market Industry Analysis Report 2021-2028 - A US$1.83 Billion Market by 2028 - ResearchAndMarkets.com

Retrieved on: 
Thursday, February 18, 2021
Medical devices, Health, Biotechnology, Branches of biology, Chemical pathology, D-dimer, Fibrinolytic system, Aptamer, Market segmentation, Market share, Articles, Life sciences

The "D-dimer Testing Market Share, Size, Trends, Industry Analysis Report, By Product; By Testing Method; By Application; By End-Use; By Regions; Segment Forecast, 2021-2028" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "D-dimer Testing Market Share, Size, Trends, Industry Analysis Report, By Product; By Testing Method; By Application; By End-Use; By Regions; Segment Forecast, 2021-2028" report has been added to ResearchAndMarkets.com's offering.
  • The global D-dimer testing market is expected to reach US$1.83 billion by 2028.
  • The global market for D-dimer testing is fragmented based on the product, method, application, end-use, and region.
  • The reagents & consumables market segment accounted for the largest revenue share of the global D-dimer testing industry in 2020 owing to the availability of ready made aptamers.

Global D-dimer Testing Industry

Retrieved on: 
Wednesday, November 18, 2020
Chemical pathology, D-dimer, Fibrinolytic system

US D-dimer Testing Market Share (in %) by Company: 2019 & 2025

Key Points: 
  • US D-dimer Testing Market Share (in %) by Company: 2019 & 2025
    Projections in US$ Thousand by Testing Method: 2020 to 2027
    in US$ Thousand by Application: 2020 to 2027
    Forecasts in US$ Thousand by Testing Method: 2020 to 2027
    Testing Method in US$ Thousand: 2012-2019
    Table 30: D-dimer Testing Market in Canada: Percentage Share
    Breakdown of Sales by Testing Method for 2012, 2020, and 2027
    Analysis in US$ Thousand by Application: 2020 to 2027
    Table 32: D-dimer Testing Market in Canada: Summarization of
    Table 34: Japanese Market for D-dimer Testing: Annual Sales
    Table 35: D-dimer Testing Market in Japan: Historic Sales
    Testing in US$ Thousand by Application: 2020 to 2027
    US$ Thousand by Testing Method: 2012-2019
    Table 42: Chinese D-dimer Testing Market by Testing Method:
    Percentage Breakdown of Sales for 2012, 2020, and 2027
    Table 47: D-dimer Testing Market in Europe: A Historic Market
    Forecasts in US$ Thousand by Testing Method: 2020-2027
    Opportunity in US$ Thousand by Application: 2020-2027
    Table 53: D-dimer Testing Market in Europe: Summarization of
    Table 55: D-dimer Testing Market in France by Testing Method:
    US$ Thousand by Testing Method: 2012-2019
    France in US$ Thousand by Application: 2020-2027
    Table 60: French D-dimer Testing Market Share Analysis:
    A 17-Year Perspective by Application for 2012, 2020, and 2027
    Table 61: D-dimer Testing Market in Germany: Recent Past,
    US$ Thousand by Testing Method: 2012-2019
    Table 64: D-dimer Testing Market in Germany: Annual Sales
    US$ Thousand by Testing Method: 2012-2019
    Table 69: Italian D-dimer Testing Market by Testing Method:
    Percentage Breakdown of Sales for 2012, 2020, and 2027
    Table 73: United Kingdom Market for D-dimer Testing: Annual
    Table 74: D-dimer Testing Market in the United Kingdom:
    D-dimer Testing in US$ Thousand by Application: 2020 to 2027
    Forecasts in US$ Thousand by Testing Method: 2020-2027
    Opportunity in US$ Thousand by Application: 2020-2027
    Table 83: D-dimer Testing Market in Rest of Europe:
    in US$ Thousand by Testing Method: 2012-2019
    Asia-Pacific in US$ Thousand by Application: 2020-2027
    in US$ Thousand by Application: 2012-2019
    Table 90: Asia-Pacific D-dimer Testing Market Share Analysis:
    A 17-Year Perspective by Application for 2012, 2020, and 2027
    Forecasts in US$ Thousand by Testing Method: 2020 to 2027
    by Testing Method in US$ Thousand: 2012-2019
    Table 93: D-dimer Testing Market in Rest of World: Percentage
    Share Breakdown of Sales by Testing Method for 2012, 2020, and
    Demand Analysis in US$ Thousand by Application: 2020 to 2027
    Table 95: D-dimer Testing Market in Rest of World:

Liminal BioSciences Announces Upcoming Presentations for Ryplazim® (plasminogen) at the 62nd ASH Annual Meeting and Exposition

Retrieved on: 
Thursday, November 5, 2020
Fibrinolytic system, Liminal BioSciences, Plasmin, Food and Drug Administration, Liminal, Branches of biology, Life sciences, Health care

Patients with congenital plasminogen deficiency experience an accumulation of fibrin growths or lesions on mucosal surfaces throughout the body.

Key Points: 
  • Patients with congenital plasminogen deficiency experience an accumulation of fibrin growths or lesions on mucosal surfaces throughout the body.
  • Liminal Biosciences has received Rare Pediatric Disease and Orphan Drug Designations from the FDA for Ryplazim.
  • This press release contains forward-looking statements about Liminal BioSciences' objectives, strategies and businesses that involve risks and uncertainties.
  • Such risks may be amplified by the COVID-19 pandemic and its potential impact on Liminal BioSciences' business and the global economy.

Aniara Diagnostica Launches MORE Microsites: 5d-stabilize.com and aprotininproducts.com

Retrieved on: 
Tuesday, October 27, 2020
Enzymes, Blood, Branches of biology, Peptidase, Fibrinolytic system, Post-translational modification, Fibrinolysis, Urokinase, Protease, Aprotinin, Serine protease, Plasmin

Current uses concern protein isolation, removal of reactive proteases through solid phase, inhibition of undesired proteolytic activity in laboratory assays, or other techniques; for blocking fibrinolytic activity in vitro.

Key Points: 
  • Current uses concern protein isolation, removal of reactive proteases through solid phase, inhibition of undesired proteolytic activity in laboratory assays, or other techniques; for blocking fibrinolytic activity in vitro.
  • Aprotinin is a multiple inhibitor of many serine proteases, including Trypsin, Plasmin, Urokinase, Kallicrein, Factor XIIa.
  • The entire Aniara product line is available for purchase at http://www.aniara.com .
  • The Company distributes products in North America, Central America, South America, Sweden, Norway, Denmark, Finland, Lithuania, Latvia, Estonia and Iceland.

New Research Paper Suggests RegeneRx's Thymosin Beta 4 May be Useful in Treating COVID-19

Retrieved on: 
Tuesday, September 8, 2020
Kinin–kallikrein system, Branches of biology, Anatomy, Animal physiology, Hematology, Fibrinolytic system, Bradykinin, Angiotensin-converting enzyme, Beta thymosins, Fibrinolysis, Thrombus, Coronavirus disease

According to the scientific team, an increase of fibrinolysis could be achieved by increasing ACE, or by administering T4.

Key Points: 
  • According to the scientific team, an increase of fibrinolysis could be achieved by increasing ACE, or by administering T4.
  • Blood clots in the blood stream and organs of patients with COVID-19 have been shown to lead to extensive morbidity and patient death.
  • These bradykinin-driven outcomes suggest that a bradykinin storm may be responsible for many of the more severe symptoms of COVID.
  • RegeneRx is focused on the development of novel therapeutic peptides, including Thymosin beta 4 (T4) and its constituent fragments, for tissue and organ protection, repair, and regeneration.

Monopar Announces Plan to Advance Development of Novel Triage Test for Severe COVID-19 Utilizing its Patented Technology

Retrieved on: 
Wednesday, August 12, 2020
Medical specialties, Branches of biology, Clinical medicine, Clusters of differentiation, SuPAR, Immunology, Fibrinolytic system, Urokinase receptor, Suparnostic, Urokinase, Plasminogen activator, Plasmin

The test would use Monopars proprietary monoclonal antibody, ATN-658, to detect soluble urokinase plasminogen activator receptor (suPAR) in COVID-19 patient plasma.

Key Points: 
  • The test would use Monopars proprietary monoclonal antibody, ATN-658, to detect soluble urokinase plasminogen activator receptor (suPAR) in COVID-19 patient plasma.
  • The aim is to clinically validate the suPAR-based test in COVID-19 patients.
  • The use of suPAR for triaging COVID-19 patients is supported by a growing body of recent studies.
  • All forward-looking statements contained in this press release speak only as of the date on which they were made.

NoNO Inc. Reports Groundbreaking Results from the Phase 3 ESCAPE-NA1 Study of the Peptide, Nerinetide, in Acute Ischemic Stroke

Retrieved on: 
Thursday, February 20, 2020
Hoffmann-La Roche, Fibrinolytic system, Alteplase, Boehringer Ingelheim, Genentech, Drugs, Branches of biology, Plasmin, NONO

*Outcomes between the alteplase and no alteplase participants cannot be compared as they are different populations.

Key Points: 
  • *Outcomes between the alteplase and no alteplase participants cannot be compared as they are different populations.
  • Separate non-clinical studies by NoNO Inc. have shown that prior alteplase administration can lower plasma nerinetide concentrations because alteplase activates plasmin, an enzyme that cleaves nerinetide.
  • The study provides evidence of the validity of a biological pathway that protects brain cells from dying when they are deprived of blood flow.
  • NoNO Inc. is an Ontario biotechnology company whose focus is on developing therapeutic drugs in areas of unmet medical needs.

2020 Alpha-2 Antiplasmin Testing Market: USA, Japan & Europe, Including Germany, France, Spain, Italy & the UK - ResearchAndMarkets.com

Retrieved on: 
Thursday, February 6, 2020
Research, Science, Blood, Anatomy, Fibrinolytic system, Body fluids, Alpha 2-antiplasmin, Coagulation, Plasmin

The "2020 Alpha-2 Antiplasmin Testing Market: USA, Europe, Japan - Competitive Strategies, Country Forecasts, Innovative technologies and Instrumentation" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "2020 Alpha-2 Antiplasmin Testing Market: USA, Europe, Japan - Competitive Strategies, Country Forecasts, Innovative technologies and Instrumentation" report has been added to ResearchAndMarkets.com's offering.
  • The growing cost-containment pressures in major industrialized nations and continued technological advances will radically change coagulation testing practice during the next five years.
  • Coagulation testing in general, and Alpha-2 Antiplasmin testing specifically, will become more standardized, offering opportunities for quality control products and services.
  • This report presents a detailed analysis of the Alpha-2 Antiplasmin testing market in the US, Europe (France, Germany, Italy, Spain, UK) and Japan, including clinical significance and current laboratory practice, as well as 5-year test volume forecasts by country and market segment.

Plasminogen Activator Inhibitor 1, Pipeline Review, H2 2019 - Beam Therapeutics Inc, Jazz Pharmaceuticals Plc & MDI Therapeutics Inc - ResearchAndMarkets.com

Retrieved on: 
Monday, January 20, 2020
Biotechnology, Pharmaceutical, Health, Blood, Fibrinolytic system, Branches of biology, Anatomy, Serine protease inhibitors, Hematology, Plasminogen activator inhibitor-1, Plasminogen activator, Pai, Plasmin, Serpin, Tiplasinin

According to the recently published report 'Plasminogen Activator Inhibitor 1 - Pipeline Review, H2 2019'; Plasminogen Activator Inhibitor 1 (Endothelial Plasminogen Activator Inhibitor or PAI1 or SERPINE1) pipeline Target constitutes close to 12 molecules.

Key Points: 
  • According to the recently published report 'Plasminogen Activator Inhibitor 1 - Pipeline Review, H2 2019'; Plasminogen Activator Inhibitor 1 (Endothelial Plasminogen Activator Inhibitor or PAI1 or SERPINE1) pipeline Target constitutes close to 12 molecules.
  • Plasminogen Activator Inhibitor 1 (Endothelial Plasminogen Activator Inhibitor or PAI1 or SERPINE1) - Plasminogen activator inhibitor-1 (PAI-1) also known as endothelial plasminogen activator inhibitor or is a protein that encodes by the SERPINE1 gene.
  • The report 'Plasminogen Activator Inhibitor 1 - Pipeline Review, H2 2019' outlays comprehensive information on the Plasminogen Activator Inhibitor 1 (Endothelial Plasminogen Activator Inhibitor or PAI1 or SERPINE1) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type; that are being developed by Companies / Universities.
  • It also reviews key players involved in Plasminogen Activator Inhibitor 1 (Endothelial Plasminogen Activator Inhibitor or PAI1 or SERPINE1) targeted therapeutics development with respective active and dormant or discontinued projects.